| RSS
Business center
Office
Post trade leads
Post
Rank promotion
Ranking
 
You are at: Home » News » internal »

BMS Acquires Licence from Novo for a Discovery Research Program Focused on Autoimmune Diseases

Increase font size  Decrease font size Date:2015-03-30   Views:351

Bristol-Myers Squibb Company (BMS) has announced the company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global licence to a discovery biologics research programme focused on modulating the innate immune system as a therapy for autoimmune diseases. Terms of the agreement were not disclosed.

 

The agreement supports BMS’s long-standing commitment to immunoscience, a core therapeutic area with multiple innovative drug candidates in development to target immune-mediated diseases with high unmet medical needs.

 

The innate immune system is the body’s first line of defense against pathogens and responds to exogenous agents in an antigen non-specific way to stimulate an immediate protective response. Dysregulated innate immunity plays a critical role in the induction and pathogenesis of autoimmune diseases.

 
 
[ Search ]  [ ]  [ Email ]  [ Print ]  [ Close ]  [ Top ]

 
Total:0comment(s) [View All]  Related comment

 
Recomment
Popular
 
 
Home | About | Service | copyright | agreement | contact | about | SiteMap | Links | GuestBook | Ads service | 京ICP 68975478-1
Tel:+86-10-68645975           Fax:+86-10-68645973
E-mail:yaoshang68@163.com     QQ:1483838028